Pivot Pharmaceuticals Receives Conditional Approval for CSE
Vancouver, British Columbia (FSCwire) - Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) (“Pivot” or the “Company”), an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals, is pleased to announce that the Company has received conditional approval to list its Common Shares on the Canadian Securities Exchange (“CSE”). Final approval is subject to the filing of and receipt for a final prospectus and the completion of customary listing requirements of the CSE, including receipt of all required documentation.
The CSE is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to “provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.” As a “Designated Stock Exchange” all securities on the CSE are both RRSP and TFSA eligible.
Dr. Patrick Frankham, Pivot’s CEO, states “The Company continues to successfully execute on its business plan and the receipt of a conditional listing approval from the CSE is another significant achievement for Pivot. The listing will allow Pivot to expand its shareholder base and gain access to capital markets in Canada. We look forward to welcoming new investors that share our vision of becoming the next vertical in the development and commercialization of cannabis-based health products.”
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. PGS will seek to register these as Natural Health Products (“NHP”) for consumers. Products following the NHP pathway have shorter development cycles and can generate revenue faster than traditional pharmaceuticals. For more information please visit www.PivotPharma.com
Cautionary Statement
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or Pivot Green Stream, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. While management believes that final approval for listing on the CSE is forthcoming numerous factors could delay that approval or cause the denial of such approval. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot's products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/Pivot11202017.pdf
Source: Pivot Pharmaceuticals Inc. (OTCQB:PVOTF)
To follow Pivot Pharmaceuticals Inc. on your favorite social media platform or financial websites, please click on the icons below.
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2017 Filing Services Canada Inc.